{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:11:33Z","timestamp":1792689093453,"version":"4.5.0"},"reference-count":165,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.revmed.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:22:03Z","timestamp":1750432923000},"page":"449-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-549X","authenticated-orcid":false,"given":"Pierre","family":"Quartier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-3891","authenticated-orcid":false,"given":"Sylvain","family":"Breton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Carbasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Devauchelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Georgin-Lavialle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Jurquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-5763","authenticated-orcid":false,"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8761-2020","authenticated-orcid":false,"given":"Ir\u00e8ne","family":"Lemelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Meinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Melki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Pillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lo\u00efse","family":"Reumaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Rossi-Semerano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Uettwiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Grall-Lerosey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Hentgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Merlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Pajot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2025.06.001_bib0830","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib0835","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/BOR.0000000000000637","article-title":"Implications of juvenile idiopathic arthritis genetic risk variants for disease pathogenesis and classification","volume":"31","author":"Nigrovic","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib0840","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib0845","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.20945","article-title":"Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease","volume":"52","author":"Ravelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2025.06.001_bib0850","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib0855","first-page":"343","article-title":"Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR)","volume":"35","author":"Behrens","year":"2008","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib0860","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/art.22709","article-title":"Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor","volume":"56","author":"Saurenmann","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib0865","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.annder.2016.02.006","article-title":"Impact of sex and age on the clinical and epidemiological aspects of childhood psoriasis: data from a French cross-sectional multicentre study","volume":"143","author":"Bonigen","year":"2016","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.revmed.2025.06.001_bib0870","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.annder.2017.10.008","article-title":"Psoriatic arthritis in France, from infants to the elderly: findings from two cross-sectional multicenter studies","volume":"145","author":"Galezowski","year":"2018","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.revmed.2025.06.001_bib0875","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib0880","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.berh.2009.07.001","article-title":"Developing outcome measures for paediatric rheumatic diseases","volume":"23","author":"Brunner","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.revmed.2025.06.001_bib0885","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","article-title":"Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score","volume":"64","author":"Consolaro","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib0890","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/art.22900","article-title":"Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis","volume":"57","author":"Filocamo","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2025.06.001_bib0895","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","article-title":"Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany","volume":"16","author":"Hinze","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib0900","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.22357","article-title":"Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease","volume":"55","author":"Palmisani","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib0905","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1297-319X(02)00432-3","article-title":"Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis","volume":"69","author":"Pouchot","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2025.06.001_bib0910","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9563","key":"10.1016\/j.revmed.2025.06.001_bib0915","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2025.06.001_bib0920","series-title":"Pediatrics in systemic autoimmune diseases (Handbook of systemic autoimmune diseases series)","article-title":"Systemic juvenile idiopathic arthritis","author":"Schneider","year":"2008"},{"issue":"7","key":"10.1016\/j.revmed.2025.06.001_bib0925","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.revmed.2025.06.001_bib0930","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib0935","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/ket318","article-title":"Juvenile idiopathic arthritis and malignancy","volume":"53","author":"Ruperto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2025.06.001_bib0940","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/art.38359","article-title":"Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-\u03b3","volume":"66","author":"Avau","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"10.1016\/j.revmed.2025.06.001_bib0945","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.06.001_bib0950","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.rdc.2021.06.003","article-title":"Pathogenesis and treatment of refractory disease courses in systemic juvenile idiopathic arthritis: refractory arthritis, recurrent macrophage activation syndrome and chronic lung disease","volume":"47","author":"Erkens","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.revmed.2025.06.001_bib0955","doi-asserted-by":"crossref","first-page":"e147593","DOI":"10.1172\/jci.insight.147593","article-title":"IFN-\u03b3 is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome","volume":"6","author":"Gao","year":"2021","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib0960","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/acr.21889","article-title":"Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis","volume":"65","author":"Kimura","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.revmed.2025.06.001_bib0965","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2025.06.001_bib0970","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","article-title":"Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome","volume":"119","author":"Mizuta","year":"2019","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib0975","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2025.06.001_bib0980","doi-asserted-by":"crossref","first-page":"15785","DOI":"10.1073\/pnas.1521837113","article-title":"Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis","volume":"112","author":"Nigrovic","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib0985","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","article-title":"Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB115 alleles","volume":"81","author":"Saper","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.06.001_bib0990","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1073\/pnas.1520779112","article-title":"HLA-DRB111 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis","volume":"112","author":"Ombrello","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.revmed.2025.06.001_bib0995","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.berh.2018.02.002","article-title":"Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies","volume":"31","author":"Pardeo","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1000","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/art.41488","article-title":"Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb\/IV open-label, randomized study","volume":"73","author":"Quartier","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1005","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib1010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.06.001_bib1015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Biologic therapy modifies clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2025.06.001_bib1020","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1025","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.06.001_bib1030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1035","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/2050-6511-14-40","article-title":"Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes","volume":"14","author":"Urien","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.revmed.2025.06.001_bib1045","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"Suppl. 6","key":"10.1016\/j.revmed.2025.06.001_bib1050","doi-asserted-by":"crossref","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still's disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.revmed.2025.06.001_bib1055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/art.38877","article-title":"Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis","volume":"67","author":"Wakil","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.revmed.2025.06.001_bib1060","doi-asserted-by":"crossref","first-page":"e000036","DOI":"10.1136\/rmdopen-2014-000036","article-title":"Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent","volume":"1","author":"Woerner","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.revmed.2025.06.001_bib1065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2025.06.001_bib1070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard-2022-222849","article-title":"Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial","volume":"82","author":"Brunner","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1075","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.06.001_bib1080","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2025.06.001_bib1085","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.39145","article-title":"Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.24087","article-title":"Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis","volume":"61","author":"Albers","year":"2009","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2025.06.001_bib1095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.06.001_bib1100","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.semarthrit.2016.10.008","article-title":"Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review","volume":"46","author":"Davies","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"13","key":"10.1016\/j.revmed.2025.06.001_bib1110","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs. 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"Foell","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2025.06.001_bib1115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.06.001_bib1120","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"10401","key":"10.1016\/j.revmed.2025.06.001_bib1125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"issue":"10072","key":"10.1016\/j.revmed.2025.06.001_bib1130","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","article-title":"Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial","volume":"389","author":"Ravelli","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"10.1016\/j.revmed.2025.06.001_bib1135","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/acr.22259","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis","volume":"66","author":"Ringold","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2025.06.001_bib1140","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2025.06.001_bib1145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.revmed.2025.06.001_bib1150","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/ard.2007.087130","article-title":"Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis","volume":"68","author":"Tynj\u00e4l\u00e4","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.revmed.2025.06.001_bib1155","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9636","key":"10.1016\/j.revmed.2025.06.001_bib1160","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.revmed.2025.06.001_bib1165","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynj\u00e4l\u00e4","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1170","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib1175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib1180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-005-0087-3","article-title":"Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature","volume":"244","author":"Carvounis","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1185","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1542\/peds.2006-0421","article-title":"Ophthalmologic examinations in children with juvenile rheumatoid arthritis","volume":"117","author":"Cassidy","year":"2006","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1190","first-page":"1139","article-title":"Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease","volume":"34","author":"Grassi","year":"2007","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1195","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/rheumatology\/kem053","article-title":"Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines","volume":"46","author":"Heiligenhaus","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1200","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/ard.2004.026955","article-title":"Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients","volume":"64","author":"Kotaniemi","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2025.06.001_bib1205","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2006.05.016","article-title":"Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis","volume":"113","author":"Kump","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2025.06.001_bib1210","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2003.07.011","article-title":"Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis","volume":"111","author":"Monnet","year":"2004","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.revmed.2025.06.001_bib1215","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09273940590909220","article-title":"Visual outcome of juvenile rheumatoid arthritis-associated uveitis in adults","volume":"13","author":"Ozdal","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2025.06.001_bib1220","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.06.001_bib1225","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMc1708646","article-title":"Adalimumab for uveitis in juvenile idiopathic arthritis","volume":"377","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2025.06.001_bib1230","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"300","key":"10.1016\/j.revmed.2025.06.001_bib1235","first-page":"67","article-title":"Visual outcome in children with juvenile idiopathic arthritis related uveitis","author":"Raymaekers","year":"2006","journal-title":"Bull Soc Belge Ophtalmol"},{"issue":"12","key":"10.1016\/j.revmed.2025.06.001_bib1240","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.ophtha.2004.06.014","article-title":"Ocular complications of pediatric uveitis","volume":"111","author":"Rosenberg","year":"2004","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib1245","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/art.22381","article-title":"Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow-up study","volume":"56","author":"Saurenmann","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1250","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09273940600977233","article-title":"Extended oligoarthritis and other risk factors for developing JIA-associated uveitis under ILAR classification and its implication for current screening guideline","volume":"14","author":"Sim","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1255","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ajo.2007.01.033","article-title":"Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss","volume":"143","author":"Thorne","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib1260","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis","volume":"47","author":"Tynj\u00e4l\u00e4","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.revmed.2025.06.001_bib1265","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2006.11.025","article-title":"Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis","volume":"143","author":"Woreta","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1270","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.revmed.2023.04.002","article-title":"French recommendations for the management of non-infectious chronic uveitis","volume":"44","author":"Quartier","year":"2023","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2025.06.001_bib1275","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1136\/annrheumdis-2020-216983","article-title":"Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report","volume":"81","author":"Bader-Meunier","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.06.001_bib1280","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12969-015-0055-3","article-title":"Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"13","author":"Boom","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"10.1016\/j.revmed.2025.06.001_bib1285","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.22656","article-title":"Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial","volume":"56","author":"Brinkman","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.revmed.2025.06.001_bib1290","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12969-020-00444-7","article-title":"Next gen therapies for systemic juvenile idiopathic arthritis and macrophage activation syndrome symposium held on October 3\u20134, 2019","volume":"18","author":"Canna","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.revmed.2025.06.001_bib1295","first-page":"9323141","article-title":"Allogeneic hematopoietic cell transplant for systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"2021","author":"Davidson","year":"2021","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1300","series-title":"Efficacy of emapalumab, an anti-IFN\u03b3 antibody in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA)","author":"De Benedetti","year":"2021"},{"issue":"12","key":"10.1016\/j.revmed.2025.06.001_bib1305","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kel319a","article-title":"Autologous haematopoeitic stem cell rescue (AHSCR) for severe rheumatic disease in children: guidance for BSPAR members\u00a0\u2013\u00a0executive summary","volume":"45","author":"Foster","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1310","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jbspin.2006.12.004","article-title":"Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis","volume":"74","author":"Garc\u00eda-Carrasco","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2025.06.001_bib1315","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome-hemophagocytic lymphohistiocytosis","volume":"48","author":"Horne","year":"2021","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1320","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jpeds.2004.08.020","article-title":"Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study","volume":"145","author":"Lehman","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.revmed.2025.06.001_bib1325","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","article-title":"Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis","volume":"2","author":"M","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2025.06.001_bib1330","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12969-021-00523-3","article-title":"Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis","volume":"19","author":"Morelle","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.revmed.2025.06.001_bib1340","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","article-title":"Intravenous administration of anakinra in children with macrophage activation syndrome","volume":"19","author":"Phadke","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1345","first-page":"625","article-title":"Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis","volume":"17","author":"Ravelli","year":"1999","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1350","first-page":"985","article-title":"Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension","volume":"33","author":"Reiff","year":"2006","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1355","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s11926-005-0047-2","article-title":"The use of anakinra in juvenile arthritis","volume":"7","author":"Reiff","year":"2005","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1360","first-page":"599","article-title":"Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG\/PRINTO phase IV post marketing surveillance study","volume":"24","author":"Ruperto","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2025.06.001_bib1365","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12969-020-0399-1","article-title":"Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"18","author":"Shimizu","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"issue":"16","key":"10.1016\/j.revmed.2025.06.001_bib1370","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib1375","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/art.20861","article-title":"Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis","volume":"52","author":"Silverman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2025.06.001_bib1380","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","article-title":"Interfering with Interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)","volume":"61","author":"Verweyen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2025.06.001_bib1385","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpeds.2018.08.065","article-title":"Risk of serious infections associated with biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analyses","volume":"204","author":"Aeschlimann","year":"2019","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib1390","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.11010","article-title":"Pain in children with arthritis: a review of the current literature","volume":"49","author":"Anthony","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.revmed.2025.06.001_bib1395","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1210\/jc.2007-0544","article-title":"Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study","volume":"92","author":"Bechtold","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1400","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib1405","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/berh.2002.0236","article-title":"Osteoporosis in childhood rheumatic diseases: prevention and therapy","volume":"16","author":"Cimaz","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1410","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/BOR.0b013e32825a6a79","article-title":"Recognition and management of macrophage activation syndrome in juvenile arthritis","volume":"19","author":"Kelly","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib1415","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/art.20963","article-title":"A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis","volume":"52","author":"Lien","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1420","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","article-title":"Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"146","author":"Ravelli","year":"2005","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1425","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/rheumatology\/keh538","article-title":"Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment","volume":"44","author":"Rudge","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1430","first-page":"1296","article-title":"Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids","volume":"29","author":"Simon","year":"2002","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.revmed.2025.06.001_bib1435","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1210\/jc.2006-2877","article-title":"Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study","volume":"92","author":"Simon","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.revmed.2025.06.001_bib1440","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jpeds.2005.11.043","article-title":"A randomized clinical trial of dietary calcium to improve bone accretion in children with juvenile rheumatoid arthritis","volume":"148","author":"Stark","year":"2006","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.revmed.2025.06.001_bib1445","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/adc.2006.093997","article-title":"Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis","volume":"91","author":"Thornton","year":"2006","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.revmed.2025.06.001_bib1450","first-page":"CD005324","article-title":"Bisphosphonate therapy for children and adolescents with secondary osteoporosis","author":"Ward","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2025.06.001_bib1455","series-title":"\u00c9ducation th\u00e9rapeutique du patient en rhumatologie","author":"Beauvais","year":"2015"},{"key":"10.1016\/j.revmed.2025.06.001_bib1460","series-title":"\u00c9ducation th\u00e9rapeutique du patient. Guide de la Haute Autorit\u00e9 de sant\u00e9","year":"2016"},{"key":"10.1016\/j.revmed.2025.06.001_bib1465","series-title":"Rapport de l\u2019OMS-Europe. Therapeutic Patient Education\u00a0\u2013\u00a0Continuing Education Programmes for Health Care Providers in the field of Chronic Disease, traduit en fran\u00e7ais en 1998","year":"1996"},{"key":"10.1016\/j.revmed.2025.06.001_bib1470","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.rhum.2014.04.009","article-title":"Recommandations de la Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie pour la prise en charge de la polyarthrite rhumato\u00efde","volume":"81","author":"Gaujoux-Vial","year":"2014","journal-title":"Rev Rhum"},{"issue":"5 Suppl. 31","key":"10.1016\/j.revmed.2025.06.001_bib1475","first-page":"S89","article-title":"Early predictors of outcome in juvenile idiopathic arthritis","volume":"21","author":"Ravelli","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1480","first-page":"579","article-title":"Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10-year follow-up","volume":"30","author":"Fantini","year":"2003","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib1485","first-page":"491","article-title":"Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years","volume":"27","author":"Lomater","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1490","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.41612","article-title":"Early treatment and IL1RN single-nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis","volume":"73","author":"Pardeo","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"5 Suppl. 31","key":"10.1016\/j.revmed.2025.06.001_bib1495","first-page":"S89","article-title":"Early predictors of outcome in juvenile idiopathic arthritis","volume":"21","author":"Ravelli","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1500","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3899\/jrheum.180331","article-title":"Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis","volume":"46","author":"Saccomanno","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1505","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.21774","article-title":"Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features","volume":"54","author":"Singh-Grewal","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1510","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.21774","article-title":"Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features","volume":"54","author":"Singh-Grewal","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2025.06.001_bib1515","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3389\/fphar.2019.00918","article-title":"Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease","volume":"10","author":"Sota","year":"2019","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.revmed.2025.06.001_bib1520","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/art.21389","article-title":"Patterns of clinical remission in select categories of juvenile idiopathic arthritis","volume":"52","author":"Wallace","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib1525","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.semarthrit.2010.12.005","article-title":"Comparison of clinical and ultrasonographic evaluations for peripheral synovitis in juvenile idiopathic arthritis","volume":"41","author":"Breton","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1530","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.semarthrit.2011.08.004","article-title":"Imaging approaches for evaluating peripheral joint abnormalities in juvenile idiopathic arthritis","volume":"41","author":"Breton","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.revmed.2025.06.001_bib1535","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/annrheumdis-2015-207892","article-title":"EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice","volume":"74","author":"Colebatch-Bourn","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.revmed.2025.06.001_bib1540","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jbspin.2014.05.002","article-title":"Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis","volume":"81","author":"Gaujoux-Viala","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2025.06.001_bib1545","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3899\/jrheum.131064","article-title":"Diagnostic utility of magnetic resonance imaging and radiography in juvenile spondyloarthritis: evaluation of the sacro-iliac joints in controls and affected subjects","volume":"41","author":"Jaremko","year":"2014","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2025.06.001_bib1550","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/acr.20444","article-title":"Ultrasonography for detecting enthesitis in juvenile idiopathic arthritis","volume":"63","author":"Jousse-Joulin","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.revmed.2025.06.001_bib1555","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s00330-018-5304-7","article-title":"Conventional radiography in juvenile idiopathic arthritis: joint recommendations from the French Societies for Rheumatology, Radiology, and Paediatric Rheumatology","volume":"28","author":"Marteau","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1560","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.reuma.2016.08.008","article-title":"Recommendations for the use of ultrasound and magnetic resonance in patients with spondyloarthritis, including psoriatic arthritis, and patients with juvenile idiopathic arthritis","volume":"14","author":"Uson","year":"2018","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.revmed.2025.06.001_bib1565","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/acr.22201","article-title":"Inflamamtory changes of the lumbar spine in children and adolescents with enthesitis related arthritis: magnetic resonance imaging findings","volume":"66","author":"Vendhan","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2025.06.001_bib1570","series-title":"R\u00e9\u00e9ducation et r\u00e9adaptation de l\u2019arthrite juv\u00e9nile idiopathique. EMC Kin\u00e9sith\u00e9rapie-M\u00e9decine physique\u00a0\u2013\u00a0R\u00e9adaptation","author":"Baticle","year":"2000"},{"key":"10.1016\/j.revmed.2025.06.001_bib1575","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1169-8330(03)00189-3","article-title":"M\u00e9decine physique et r\u00e9adaptation dans les arthrites juv\u00e9niles idiopathiques","volume":"70","author":"Beltramo","year":"2003","journal-title":"Rev Rhum"},{"issue":"19","key":"10.1016\/j.revmed.2025.06.001_bib1580","first-page":"2607","article-title":"[Rehabilitation of children with chronic inflammatory arthritis]","volume":"44","author":"Beltramo","year":"1994","journal-title":"Rev Prat"},{"key":"10.1016\/j.revmed.2025.06.001_bib1585","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11659-008-0092-0","article-title":"R\u00e9\u00e9ducation de l\u2019enfant atteint d\u2019arthrite juv\u00e9nile idiopathique\u00a0: cas cliniques","volume":"24","author":"Gavillot","year":"2008","journal-title":"Lettr Med Phys Readapt"},{"issue":"8","key":"10.1016\/j.revmed.2025.06.001_bib1590","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.autrev.2010.04.001","article-title":"Evidence for prescribing exercise as treatment in pediatric rheumatic diseases","volume":"9","author":"Gualano","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib1595","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0950-3579(98)80022-8","article-title":"Rehabilitation in children with juvenile chronic arthritis","volume":"12","author":"H\u00e4fner","year":"1998","journal-title":"Baillieres Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2025.06.001_bib1600","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00393-011-0867-6","article-title":"[Physiotherapy for juvenile idiopathic arthritis]","volume":"71","author":"Spamer","year":"2012","journal-title":"Z Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2025.06.001_bib1605","first-page":"287","article-title":"Exercise therapy in juvenile idiopathic arthritis: a Cochrane review","volume":"44","author":"Takken","year":"2008","journal-title":"Eur J Phys Rehabil Med"},{"key":"10.1016\/j.revmed.2025.06.001_bib1610","series-title":"Calendrier des vaccinations et recommandations vaccinales","year":"2022"},{"issue":"7","key":"10.1016\/j.revmed.2025.06.001_bib1615","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11926-015-0519-y","article-title":"Vaccinations in paediatric rheumatology: an update on current developments","volume":"17","author":"Groot","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"10.1016\/j.revmed.2025.06.001_bib1620","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/ard.2011.150193","article-title":"EULAR recommendations for vaccination in pediatric patients with rheumatic diseases","volume":"70","author":"Heijstek","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.revmed.2025.06.001_bib1625","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.autrev.2011.08.010","article-title":"Vaccination in pediatric patients with autoimmune rheumatic diseases: a systematic literature review for the European League against Rheumatism evidence-based recommendations","volume":"11","author":"Heijstek","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.revmed.2025.06.001_bib1630","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","article-title":"EULAR\/PRES recommendations for vaccination of pediatric patients with autoimmune inflammatory rheumatic diseases: update 2021","volume":"82","author":"Jansen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2025.06.001_bib1635","series-title":"Vaccination des personnes immunod\u00e9prim\u00e9es ou aspl\u00e9niques. Recommandations","year":"2014"},{"issue":"9","key":"10.1016\/j.revmed.2025.06.001_bib1640","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.revmed.2021.02.003","article-title":"La transition de la p\u00e9diatrie \u00e0 l\u2019\u00e2ge adulte\u00a0: recommandations de prise en charge de la fili\u00e8re des maladies auto-immunes et auto-inflammatoires rares FAI2R","volume":"42","author":"Georgin-Lavialle","year":"2021","journal-title":"Rev Med Interne"},{"issue":"9","key":"10.1016\/j.revmed.2025.06.001_bib1645","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2025.06.001_bib1650","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jpeds.2017.06.005","article-title":"Development and initial validation of the macrophage activation syndrome\/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome","volume":"189","author":"Minoia","year":"2017","journal-title":"J Pediatr"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325006484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325006484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:13:36Z","timestamp":1762265616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866325006484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":165,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0248866325006484"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2025.06.001","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}